卵巢癌治疗新进展：苏维西塔单抗Ⅲ期临床数据公布

Core Insights - Ovarian cancer is one of the deadliest malignancies in the female reproductive system, with approximately 61,100 new cases and 32,600 deaths annually in China [1] - The new drug Suvemcitug has shown significant progress in treating platinum-resistant ovarian cancer, as evidenced by the results of the phase III clinical trial published in Nature Cancer [1][2] Group 1: Drug Development and Clinical Trial Results - Suvemcitug, a monoclonal antibody, targets the vascular endothelial growth factor (VEGF), which is crucial for tumor angiogenesis, thereby inhibiting tumor growth and metastasis [2] - The SCORES trial involved 421 platinum-resistant ovarian cancer patients across 55 top medical centers in China, comparing the efficacy of Suvemcitug combined with chemotherapy against chemotherapy plus placebo [2] - Results indicated that the median progression-free survival (PFS) for the Suvemcitug group was 5.5 months, compared to 2.7 months for the chemotherapy-only group, representing a 54% reduction in disease progression risk [2] - The overall survival (OS) improved from 14.0 months to 15.3 months in the Suvemcitug group, with a 23% reduction in mortality risk [2] Group 2: Regulatory Approval and Future Research - Suvemcitug is the first vascular-targeted therapy in China for the entire population of platinum-resistant ovarian cancer patients, approved by the National Medical Products Administration in June 2025 and included in the national medical insurance starting January 1, 2026 [3] - Future large-scale, multi-center studies and real-world data accumulation will enhance the clinical application guidelines for Suvemcitug, providing new options for patients with limited treatment choices [3]